Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Objectives Molnupiravir and nirmatrelvir/ritonavir each became available in the United
States (US) through the Food and Drug Administration (FDA) emergency use authorization …

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …

Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …

Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …

Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …